BIO PRODUCTION SERVICES
TARGATT™ for Bioproduction of Recombinant Proteins in Chinese Hamster Ovary (CHO) cells.
The traditional CHO antibody production method is very inefficient because it involves random gene insertion and forced amplification of transgenes. Many factors adversely affect bioproduction levels. These factors include insertion sites effects (position effects), DNA repeat-induced gene silencing and genomic instability, altered regulation or interruption of endogenous genes.
Thus, the goals of the CHO antibody production field are: a defined genomic locus with guaranteed high levels of expression, high integration efficiency and easy screening that is reproducible for any candidate protein. In addition, it is crucial that the cell line is viable and stably reproduced.
Applied StemCell has met and exceeded these goals with its proprietary TARGATT™ technology in CHO cell lines. Applied StemCell (ASC) is proud to announce the launch of our CHO Bioproduction cell line technology. ASC has created Master TARGATT™CHO cell lines for the rapid creation of new lines for high level protein and antibody expression. Applied StemCell’s TARGATT™ CHO master cell lines yield >2.5g/L of recombinant proteins in a 2-week fed-batch shake flask expression system and is easily scalable for large scale bioproduction.
TARGATTTM Genome Engineering for Animal Bioproduction
Animal bioproduction uses transgenic animal mammary gland as a bioreactor for the production of recombinant proteins. Animal bioproduction, compared to CHO bioproduction, has the advantages of lower upfront and maintenance costs, is easy to contain, control and transport, involves faster development processes and no scale-up issues, and has a unique low cost bulk holding stage (frozen milk). Existing methods used to create transgenic animals for the bioproduction of important recombinant proteins, has many limitations. For example, target genes are randomly inserted, there is no control of copy number and the yield of recombinant protein is low, usually between 1-2g/L. In addition, each new protein is a new project with different and unpredictable outcomes.
Applied StemCell has pioneered a new method to generate transgenic animals using our proprietary TARGATT™technology. This technology allows us to reproducibly, and consistently, control the knock-in locus, copy number and expression of the target protein. TARGATT™utilizes the PhiC31integrase and attP docking sites to direct the chosen target protein, with high efficiency, to a pre-selected and well characterized locus. Our method ensures high expression and eliminates position effects such as gene silencing, genomic instability and interruption of endogenous genes.